Drug Trial Radar · NCT06003426
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,255
Actual
Start
Sep 14, 2023
Primary completion
Oct 6, 2026
Study completion Jun 4, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
BMS-986278Drug
Specified dose on specified days
BMS-986278 PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants that experience spontaneous syncopal eventsTime frame: At approximately 4 weeks
- Absolute change from baseline in forced vital capacity (FVC) measured in mLTime frame: Up to Week 52
Locations
390 sites in 33 countries. Site status is shown where the registry gives one.
Local Institution - 0189
Birmingham, Alabama
Local Institution - 0361
Phoenix, Arizona
Local Institution - 0396
La Jolla, California
Local Institution - 0193
Los Angeles, California
Local Institution - 0398
Los Angeles, California
Local Institution - 0389
Orange, California
Local Institution - 0405
Sacramento, California
Local Institution - 0185
San Francisco, California
Local Institution - 0186
Stanford, California
Local Institution - 0363
Aurora, Colorado
Local Institution - 0194
Denver, Colorado
Local Institution - 0175
New Haven, Connecticut
Local Institution - 0151
Newark, Delaware
Local Institution - 0367
Washington D.C., District of Columbia
Local Institution - 0101
Brandon, Florida
Local Institution - 0436
Clearwater, Florida
Local Institution - 0425
DeBary, Florida
Local Institution - 0079
Gainesville, Florida
Local Institution - 0352
Hialeah, Florida
Local Institution - 0370
Kissimmee, Florida
Local Institution - 0502
Leesburg, Florida
Local Institution - 0153
Loxahatchee Groves, Florida
Local Institution - 0187
Ocala, Florida
Local Institution - 0418
Pensacola, Florida
Local Institution - 0206
St. Petersburg, Florida
Local Institution - 0364
Tampa, Florida
Local Institution - 0372
Dublin, Georgia
Local Institution - 0178
Chicago, Illinois
Local Institution - 0183
Chicago, Illinois
Local Institution - 0058
Chicago, Illinois
Local Institution - 0085
Maywood, Illinois
Local Institution - 0325
Peoria, Illinois
Local Institution - 0180
Iowa City, Iowa
Local Institution - 0204
Kansas City, Kansas
Local Institution - 0393
Louisville, Kentucky
Local Institution - 0354
Baltimore, Maryland
Local Institution - 0380
Boston, Massachusetts
Local Institution - 0040
Boston, Massachusetts
Local Institution - 0472
Ann Arbor, Michigan
Local Institution - 0096
Chesterfield, Missouri
Showing 40 of 390 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.